ArticlePLoS neglected tropical diseases2026
Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cryptococcosis is a major health threat among immunocompromised individuals, resulting in life-threatening consequences secondary to brain invasion. The limited treatment options and the increased incidence of treatment failure and relapses urge the need for more effective therapies. In this study, we investigated the therapeutic potential of nitroxoline (NTX) in treating cryptococcal infection. NTX exhibited potent fungicidal activity against Cryptococcus neoformans/gattii clinical isolates, with an MIC90 of 1 µg/mL. In addition, NTX substantially inhibits the main virulence traits of cryptococcal cells, including the polysaccharide capsule, melanin production, and the urease enzyme, which are crucial for the infection progression. In exploring the potential mechanism of action, our results revealed the relationship between the metal-chelating properties of the NTX scaffold and its antifungal activity. Interfering metal chelation, either through structural modification or exogenous supplementation with varied divalent cations, significantly reduced the antifungal and anti-virulence activities of NTX. Given its potential therapeutic role, we evaluated the interaction between NTX and the clinically used antifungals amphotericin B, flucytosine and fluconazole. Additionally, we investigated the tendency of cryptococcal cells to develop resistance following repeated exposure to NTX, as well as its efficacy in the Caenorhabditis elegans nematode model of cryptococcal infection. Notably, cryptococcal cells exhibited consistent susceptibility to NTX upon repeated exposure to a subinhibitory concentration. In the C. elegans model, NTX significantly reduced the fungal burden of the infected worms, achieving a 2-log10 reduction, and consistently enhanced their survival compared to untreated group. These findings highlight the potential role of the NTX scaffold in combating cryptococcal infection that warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.